Asia Pacific Biomarkers Market

The Asia Pacific biomarkers market is forecasted to grow from USD 14.73 billion in 2025 to USD 26.40 billion by 2030, with a CAGR of 12.4% during the study period. The Asia Pacific biomarkers market growth is primarily attributed to the rapid expansion of clinical trials in the region and the strong growth of the CROs and CDMOs Ecosystem.

To know about the assumptions considered for the study download the pdf brochure

There are several key players in the Asia Pacific Biomarkers market, such as Thermo Fisher Scientific (US), F. Hoffmann-La Roche Ltd. (Switzerland), QIAGEN (Germany), JSR Corporation (Japan), Merck KGaA (Germany), Abbott (US), WuXi AppTec (China), Agilent Technologies (US), etc. Companies?‍?‌‍?‍‌?‍?‌‍?‍‌ in this industry are implementing plans to increase their global visibility and expand their product lines. In October 2024, JSR Corporation (Crown Biosciences) joined the Eurostars-funded MY-SIGNATURE project, led by Novigenix with Radboud University Medical Centre, to develop MYELO-SCAN, a biomarker-based liquid biopsy test targeting MDSC infiltration in mCRPC. The test aims to improve patient stratification and address therapy resistance in prostate cancer treatment.

Thermo Fisher Scientific (US) is a key player in the Asia Pacific biomarkers market. Its offerings include immunoassays, NGS workflows, and mass spectrometry platforms for discovery and routine testing. Its portfolio spans oncology, cardiovascular, infectious, and metabolic disease programs across hospitals, reference labs, and research centers. Strong collaborations with APAC cancer institutes and biopharma companies enable companion diagnostic development and extensive clinical trials. At the same time, ongoing investment in multi-omics and digital analysis tools reinforces Thermo Fisher's role in advancing precision medicine in the region.

F. Hoffmann-La Roche Ltd. (Switzerland) is one of the major players in the biomarkers market in the Asia Pacific region, and the organization brings a broad diagnostic portfolio. Biomarker development is also closely tied to precision medicine programs throughout the region. The company partners with companion diagnostics for oncology, immunology, and cardiovascular disease, and collaborates with top APAC hospitals, laboratories, and academic centres to integrate these tools into routine care. Ongoing investment in advanced molecular diagnostics, digital pathology, and personalized healthcare platforms helps maintain Roche's leadership position in shaping biomarker-driven medicine for diverse populations across the region.

QIAGEN (Germany) is a key player in the biomarkers market in the Asia-Pacific region. It is well recognized for its sample-to-insight solutions that connect high-quality sample preparation with PCR, qPCR, and NGS assays tailored to regional needs. Across the Asia Pacific, its oncology, infectious disease, and TB/HPV testing panels help hospitals, reference labs, and public health programs utilize accurate, guideline-compliant diagnostics. QIAGEN has partnerships with academic centres and local distributors, and it is increasing investment in companion diagnostics and syndromic testing, reinforcing its role in expanding access to precision medicine in the region.

Market Ranking

The Asia-Pacific biomarkers market includes global players that combine strong clinical research support with vast diagnostic and life science portfolios. Thermo Fisher Scientific plays an important role. With its wide range of in vitro diagnostics and companion diagnostics, especially in oncology and chronic disease management across advanced cancer centres and hospital networks, Roche remains a dominant force. With sample-to-insight workflows and targeted PCR/NGS panels that support infectious disease, cancer, and public health biomarker programs, QIAGEN further enhances these advantages. Together, these businesses benefit from the growing demand in Asia for scalable, clinically validated, and regulatory-compliant biomarker solutions that can be implemented across various healthcare systems.

Related Reports:

Asia Pacific Biomarkers Market by Offering (Consumables, Software, Services), Type (Safety, Efficacy), Research Area (Genomics, Proteomics), Technology (PCR, MS), Disease (Cancer, Infectious), Application (Diagnostic, Research)- Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com